Results 241 to 250 of about 1,461,609 (326)

Correction: Bispecific antibody for lung cancer: mechanisms and clinical insights. [PDF]

Front Immunol
Chen W, Zhou A, Zhou Y.
europepmc   +1 more source

Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum

Pediatric Blood &Cancer, Volume 72, Issue 9, September 2025.
ABSTRACT High‐risk neuroblastoma is a poor prognosis cancer of the sympathetic nervous system that accounts for a disproportionate number of childhood cancer deaths. Many viable biological targets have been identified, and the number of potential combinations is even larger.
Steven G. DuBois, Lucas Moreno, John Anderson, Shahab Asgharzadeh, Ro Bagatell, Maja Beck‐Popovic, Jen Belle, Pablo Berlanga, Nick J. Bird, Louis Chesler, Adam Durbin, Angelika Eggert, Martin Eilers, Sara M. Federico, Matthias Fischer, Susanne A. Gatz, Rani E. George, Sally George, Kelly C. Goldsmith, Juliet Gray, Andras Heczey, Meredith S. Irwin, Leona Knox, Holger N. Lode, Donna Ludwinski, Margaret E. Macy, Robbie G. Majzner, John M. Maris, Shakeel Modak, Jan J. Molenaar, Daniel A. Morgenstern, Yael P. Mossé, Cormac Owens, C. Patrick Reynolds, Claudia Rossig, Gudrun Schleiermacher, Liz Scott, Paul M. Sondel, Frank Speleman, Max van Noesel, Frank Westermann, Judith Wienke, Adam J. Wolpaw, Julie R. Park, Andrew D. J. Pearson   +44 more
wiley   +1 more source

Development of a bispecific CDH17-GUCY2C ADC bearing the ferroptosis inducer RSL3 for the treatment of colorectal cancer. [PDF]

Cell Death Discov
Zhang Y, Du J, Cui X, Ling Y, Tang C.
europepmc   +1 more source

GPCR‐G protein signalling and its mutational landscape in cancer—Driver or passenger

British Journal of Pharmacology, Volume 182, Issue 17, Page 3975-3989, September 2025.
G protein‐coupled receptors (GPCRs) play a crucial role in cellular signalling, regulating various physiological processes. Abnormal expression and mutations of GPCRs have been implicated in several types of cancer, influencing tumour initiation, progression and immune response.
Chenlin Feng, Jasper F. Ooms, Erik H. J. Danen, Laura H. Heitman   +3 more
wiley   +1 more source

PepMapViz: a versatile toolkit for peptide mapping, visualization, and comparative exploration. [PDF]

Bioinformatics
Zhou Z, Phung QT, Bakalarski CE.
europepmc   +1 more source

Efficacy and Safety of Bendamustine‐Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma

European Journal of Haematology, Volume 115, Issue 3, Page 260-265, September 2025.
ABSTRACT Introduction Bendamustine‐rituximab (BR) has demonstrated efficacy and tolerability in the treatment of various indolent B‐cell lymphomas, but there is limited data regarding its outcomes in nodular lymphocyte predominant B‐cell (Hodgkin) lymphoma (NLPBL).
Alexander Robin, Carolyn Owen, Sarah Perry, Lesley Street, Neil Chua, Douglas Stewart, Robert Puckrin   +6 more
wiley   +1 more source

Recent Advances in mRNA Delivery Systems for Cancer Therapy

Advanced Science, Volume 12, Issue 29, August 7, 2025.
This review systematically investigates the applications of mRNA therapy in cancer treatment, with particular emphasis on nonviral delivery systems, targeting strategies, stimulus‐responsive systems, and local delivery methods. Concluding with a meticulous evaluation, the review sheds light on the prevailing challenges while illuminating promising ...
Zheng Zhang, Ya‐Nan Fan, Si‐Qi Jiang, Ya‐Jing Ma, Yao‐Ru Yu, Yu‐Xin Qing, Qian‐Ru Li, Yi‐Lin Liu, Song Shen, Jun Wang   +9 more
wiley   +1 more source

A Reflection on the Evolution of Antibody-Based Therapies in Oncology: Trastuzumab as an Exemplar-Commentary on Dijkers et al. [PDF]

Clin Pharmacol Ther
Holstein SA.
europepmc   +1 more source

Advances in Cellular Immune Theranostic Approaches for Glioblastoma: Current Trends and Future Directions

Cancer Innovation, Volume 4, Issue 4, August 2025.
Glioblastoma (GBM) remains a highly malignant brain tumor with limited treatment efficacy, driving the need for innovative cellular immune theranostic strategies that integrate diagnostic and therapeutic approaches. Recent advances in cellular immunotherapy for GBM include chimeric antigen receptor (CAR)‐T/NK cells, macrophage‐based therapies ...
Ying Gong, Wanying Lin, Xuechun Fang, Ruyi Zhang, Min Luo, Haoran Wu, Shuai Chu, Chuangkun Li, Yiming Peng, Zhiyan Piao, Siping Wu, Junhao Li, ZongZhong He, Haixia Li, Hongxia Wang   +14 more
wiley   +1 more source